STOCK TITAN
  1. Home
  2. Sec-filings
  3. DGX
  4. [Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity

QUEST DIAGNOSTICS INC reported $11.0B in revenue and $992.0M in net income for fiscal 2025. See the full DGX financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Quest Diagnostics EVP trades shares in 10b5-1 sale

Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares. On March 4, 2026, she acquired 11,364 shares as a performance stock award at $204.86 per share, approved under Rule 16b-3(d).

On the same date, 5,806 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award at $204.86 per share. On March 5, 2026, she executed an open-market sale of 5,558 shares at an average price of $206.21 per share pursuant to a pre-established Rule 10b5-1 sales plan.

After these transactions, she directly owned 67,122 common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans, with amounts based on plan account balances and the market price of Quest Diagnostics stock.

Positive

  • None.

Negative

  • None.
Insider Doherty Catherine T.
Role EVP, Regional Businesses
Sold 5,558 shs ($1.15M)
Type Security Shares Price Value
Sale Common Stock 5,558 $206.21 $1.15M
Grant/Award Common Stock 11,364 $204.86 $2.33M
Exercise Price or Tax Liability Common Stock 5,806 $204.86 $1.19M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 67,122 shares (Direct); Common Stock — 4,502 shares (Indirect, 401(k)/SDCP)
Footnotes (4)
  1. F1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).
  2. F2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.
  3. F3. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  4. F4. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

FAQ

What insider transactions did Quest Diagnostics (DGX) EVP Catherine Doherty report?
She reported a performance stock award, tax-related share withholding, and an open-market sale. The award was 11,364 shares, 5,806 shares were withheld for taxes, and 5,558 shares were sold under a Rule 10b5-1 plan.

How many Quest Diagnostics (DGX) shares did the EVP sell and at what price?
Catherine Doherty sold 5,558 Quest Diagnostics common shares at an average price of $206.21 per share. The sale was executed on March 5, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

What stock award did the Quest Diagnostics (DGX) EVP receive in this Form 4?
She received 11,364 Quest Diagnostics common shares in settlement of a performance stock award. The shares were valued at $204.86 per share and were approved in accordance with Rule 16b-3(d) governing insider equity compensation.

Why were some Quest Diagnostics (DGX) shares disposed of back to the company?
The EVP disposed of 5,806 shares back to Quest Diagnostics solely to cover tax withholding obligations. These shares related to the settlement of the performance stock award and were valued at $204.86 per share on the transaction date.

How many Quest Diagnostics (DGX) shares does the EVP own after these transactions?
Following the reported transactions, Catherine Doherty directly owned 67,122 Quest Diagnostics common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans based on plan account balances and market price.

Were the Quest Diagnostics (DGX) insider sales part of a trading plan?
Yes. The 5,558-share sale on March 5, 2026, was executed under a Rule 10b5-1 sales plan. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Doherty Catherine T.
(Last) (First) (Middle)
500 PLAZA DRIVE
(Street)
SECAUCUS NJ 07094
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Regional Businesses
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2026 A 11,364(1) A $204.86 78,486 D
Common Stock 03/04/2026 F 5,806(2) D $204.86 72,680 D
Common Stock 03/05/2026 S(3) 5,558 D $206.21 67,122 D
Common Stock 4,502(4) I 401(k)/SDCP
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).
2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.
3. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
4. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
Remarks:
Sean D. Mersten, Attorney in Fact for Catherine T. Doherty 03/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR